UPDATE | July 24, 2025

QbD unlocked: Smarter tech transfer for biologics

  • MAIL


How does Samsung Biologics apply a quality-by-design (QbD) approach to technology transfer and process characterization for biologics? 


In the latest Contract Pharma whitepaper, our MSAT Senior Director Nilesh Deshmukh discusses the role of tech transfer and process validation in a drug’s lifecycle, design of experiments in characterization, and a case study for the monoclonal antibody process.


Read More


How does Samsung Biologics apply a quality-by-design (QbD) approach to technology transfer and process characterization for biologics? 


In the latest Contract Pharma whitepaper, our MSAT Senior Director Nilesh Deshmukh discusses the role of tech transfer and process validation in a drug’s lifecycle, design of experiments in characterization, and a case study for the monoclonal antibody process.


Read More

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required